Kan Chen
Investor, Qiming Venture Partners
Kan Chen is co-head of healthcare and partner at Qiming Venture Partners. He got his PhD from Case Western Reserve University and did his postdoctoral training at Harvard Medical School. Before joining Qiming, he was a senior scientist at JNJ. Before JNJ, he served as a group leader at Hengrui Pharmaceutical.
He is an investor in Structure Therapeutics (NASDAQ: GPCR), Abbisko (HKEX: 02256), Vor Bio (NASDAQ: VOR), Insilico Medicine (HKEX: 03696), LaNova Medicine (acquired by Sino Biopharma for $1B), Candid Tx (acquired by UCB for $2.2B), Longbio (HKEX: 01779), Serapha Bio, Medilink, Pinnacle Medicine, Vivacta, Vivatides, Chemlex, etc
He is an investor in Structure Therapeutics (NASDAQ: GPCR), Abbisko (HKEX: 02256), Vor Bio (NASDAQ: VOR), Insilico Medicine (HKEX: 03696), LaNova Medicine (acquired by Sino Biopharma for $1B), Candid Tx (acquired by UCB for $2.2B), Longbio (HKEX: 01779), Serapha Bio, Medilink, Pinnacle Medicine, Vivacta, Vivatides, Chemlex, etc